Navigation Links
Elekta to Demonstrate Latest MOSAIQ OIS Innovations for Oncology Practices at 2012 ASCO Annual Meeting
Date:5/30/2012

ATLANTA, May 30, 2012 /PRNewswire/ -- Advanced automation, sophisticated eScribe merge field capabilities and an American Cancer Society clinician portal are among the new innovations showcased in Elekta's MOSAIQ® Oncology Information System (OIS)  at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-4, at McCormick Place in Chicago.

In addition, for the sixth consecutive year, Elekta (booth #4019) has been selected to demonstrate at ASCO's EHR Vendor Lab. The 2012 Lab will be a live, in-person resource held June 2-4 in the Oncology Professionals Hall, booth #5004.

MOSAIQ is designed to manage the complete spectrum of oncology treatments in a single patient record. For chemotherapy, MOSAIQ provides a clear, flexible way to chart the patient's treatment across the medical assessment and chemotherapy administration process.

New in MOSAIQ:

  • Clinicians can bring advanced automation to the oncology practice through MOSAIQ IQ Scripts, a tool that launches a customizable "script" of activities that connect to each other. For example, IQ Scripts might be used to generate a warning message or launch an assessment based on order approval or Quality Checklist (QCL) completion. The results are exceptional control, efficiency and customization across the entire oncology workflow.
  • Enhancements to eScribe Merge Fields are available, allowing the user to put clinical, insurance, and scheduling information about the patient in eScribe documents, including the ability to add new fields instantly from a new drag-and-drop interface.
  • Oncologists will be able to launch the American Cancer Society's Clinician Portal directly from MOSAIQ, allowing instant access to their library of patient resources.
  • Full featured and integrated Survivorship module, allowing physicians to create a patient-specific treatment summary with recommendations for treatment follow up, including support resources in the community, treatment summary and recommendations for follow-up care.

MOSAIQ is the first comprehensive, oncology-specific EMR certified for meaningful use under the federal government's American Recovery and Reinvestment Act. The latest version of MOSAIQ is optimized for practices planning to demonstrate meaningful use, which qualifies them to receive payments from the Centers for Medicare & Medicaid Services (CMS) under Medicare rules.

MOSAIQ ranked first in the 2011 Best in KLAS Awards: Software & Services report. KLAS's data also are supported by the U.S. News & World Report 2011-12 best hospital rankings, which indicate that 46 out of the 50 top-ranked cancer hospitals are users of Elekta's oncology software.

"Yearly, ASCO always attracts the top minds in oncology, and we're honored to support this event," says Todd Powell, Executive Vice President, Elekta Software. "We anticipate that visitors to the Elekta exhibit will see once again why MOSAIQ is the preferred OIS for thousands of oncology practices."

Learn more at www.elekta.com/mosaiq.

For further information, please contact:
Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37, email: stina.thorman@elekta.com
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.


'/>"/>
SOURCE Elekta
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC
2. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
3. First Clinical Volumetric Modulated Arc Therapy Treatment Completed With Elekta Synergy(R) S at General Hospital Vienna
4. Elektas New Line of Stereotactic Treatment Solutions is Redefining Excellence in Stereotaxy, a Case at a Time
5. Seattles Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT
6. CMS, Inc., an Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System
7. Massachusetts General Hospital Selects Elekta As New Vendor for Complete Cancer Treatment Solution
8. National Intrepid Center of Excellence To Combat Traumatic Brain Injury With Sophisticated Brain Mapping Technology From Elekta
9. Elekta Provides Complete Planning, Treatment and Workflow Solution for Roy and Patricia Disney Family Cancer Center
10. Elekta Demonstrates Continued Leadership in Image Guidance at 2009 ASTRO Annual Meeting
11. Elekta Expands Consultative Services Program to Help MOSAIQ Customers Demonstrate Meaningful Use Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):